Introduction
Fecal microbiota transplantation (FMT) is the reference treatment for multiple-recurrent Clostridioides difficile infection (rCDI), but its use is limited by production constraints and safety concerns (1). Faecalibacterium prausnitzii is markedly depleted in rCDI and has been associated with treatment response following FMT (2), (3). EXL01, a single, unmodified strain of F. prausnitzii, was developed as a microbiota-based therapeutic. We evaluated EXL01 in a preclinical model and a phase I clinical study, with comparison to a national cohort of FMT-treated patients.
Aims & Methods
We first explored the effects of EXL01 in a murine model of antibiotic-induced CDI. We then conducted a multicenter, open-label phase I trial (2024–2025) in adults with ≥3 CDI episodes within 6 months. Following ≥10 days of vancomycin, patients received oral EXL01 for 8 weeks, with 8 weeks of follow-up. The primary endpoint was safety (treatment-related CTCAE ≥3 adverse events). Secondary endpoints included CDI recurrence. Longitudinal stool samples underwent shotgun metagenomics, and metabolomics were assessed by MS/MS (NCT06306014). Post-treatment microbiome dynamics were benchmarked against those observed after FMT in a cohort from the French Fecal Transplant Group network.
Results
In mice, EXL01 reduced C. difficile burden and intestinal inflammation. Six patients were included in the clinical study. No treatment-related serious adverse events occurred. A total of 14 non-severe adverse events were reported, six of which were considered possibly related to EXL01 (diarrhea, abdominal pain, and pyrosis); all were mild to moderate, self-limited, and did not require treatment interruption. CDI recurrence occurred in 1/6 patients (16.7%). This rate was comparable to that observed after FMT in a matched cohort from the French Fecal Transplant Group (mean efficacy 81.1%, SD 8.4). EXL01 was detectable in stool up to 8 weeks post-treatment. Multi-omics analyses showed that EXL01 engraftment was associated with restoration of bile acid metabolism and short-chain fatty acid production despite limited taxonomic recovery. These functional shifts were consistent with those observed after FMT in an independent cohort from the French Fecal Transplant Group network.
Conclusion
EXL01 showed a favorable safety profile and promising efficacy in rCDI. Treatment was associated with restoration of key microbial metabolic functions involved in colonization resistance, similar to FMT. These findings support the development of targeted microbiome therapeutics based on defined bacterial strains. A phase II randomized study is ongoing.
References
1. Benech N, Cassir N, Alric L, Barbut F, Batista R, Bleibtreu A, et al. Impact of Clinical and Pharmacological Parameters on Faecal Microbiota Transplantation Outcome in Clostridioides difficile Infections: Results of a 5-Year French National Survey. Aliment Pharmacol Ther. 10 oct 2024;
2. Khanna S, Montassier E, Schmidt B, Patel R, Knights D, Pardi DS, et al. Gut microbiome predictors of treatment response and recurrence in primary Clostridium difficile infection. Aliment Pharmacol Ther. oct 2016;44(7):715‑27.
3. Ke S, Villafuerte Gálvez JA, Sun Z, Cao Y, Pollock NR, Chen X, et al. Rational Design of Live Biotherapeutic Products for the Prevention of Clostridioides difficile Infection. J Infect Dis. 11 juill 2025;231(6):1392‑406.
Disclosure
N.B. received lecture fees and consulting fees from Tillots Pharma, Pfizer, Astrazeneca and Vedanta Bioscience and travel grants from Pfizer, Biocodex and Biotest, participated on an advisory board for Ferring Pharmaceuticals with payment to his institution, is a PI of a clinical trial supported by Exeliom Biosciences and participate in other trials supported by Vedanta Bioscience and Astrazeneca. NB participates also as a member of a Data Safety Monitoring Board of a trial supported by Clermont Ferrand University Hospital. H.S. received lecture fees, serving on boards, or providing consultancy for Carenity, AbbVie, Astellas, Danone, Ferring, Mayoly Spindler, MSD, Novartis, Roche, Tillots, Enterome, BiomX, Takeda, and Biocodex. Additionally, H.S. holds stocks in Enterome and is a co-founder of Exeliom Biosciences. A.De. received travel grants from Janssen, Pfizer, Amgen, is a PI of a clinical trial supported by Mayoli. AB received consulting fees from Ferring Pharmaceuticals and Takeda. LA received received lecture fees and consulting fees and is investigators for AbbVie, BMS, Gilead, Janssen, Merck, Novartis. C.L. received lecture fees or consulting fees for AbbVie, Johnson & Johnson, Tillots and Takeda. PM received lectures fees from Takeda; Lilly, Abbvie. Johnson. JS received lecture fees, serving on boards, or providing consultancy for Eli Lilly, Mayoly Spindler, Biocodex, Johnson & Johnson, Bromatech, Pileje, Nutriandco, Calmosine, Bioderma, Limagrain, Apothical, Novo Nordisk, Gallia, Energetica Natura, Dietaroma, Philips, Microequilibre, Bellavie, Synadiet. PL reports lecture fees, board membership, or consultancy from Biose, Biostime, Boiron, Bonduelle, BMS, Bromatech, IPSEN, iTaK, Lallemand, Lesaffre, L’Oréal, Mayoli, Merck, Procter and Gamble, Second Genome, Therascience, and URGO, and is co-founder of Exeliom Biosciences. PS and DS works for Exeliom Bioscience, co-funder of the study. The other authors report no conflicts of interest related to this work.